Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.46, for a total value of $441,900.00. Following the completion of the transaction, the chief marketing officer owned 15,000 shares of the company’s stock, valued at $441,900. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $49.10, for a total value of $736,500.00.
- On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $50.45, for a total value of $1,513,500.00.
- On Monday, February 2nd, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.02, for a total value of $690,300.00.
- On Wednesday, January 7th, Harold Bernstein sold 25,156 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.20, for a total value of $1,011,271.20.
- On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $16,480.00.
- On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.43, for a total value of $179,185.76.
Maze Therapeutics Trading Down 1.2%
Shares of Maze Therapeutics stock traded down $0.34 on Thursday, reaching $28.71. 780,343 shares of the company were exchanged, compared to its average volume of 709,583. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -8.89 and a beta of 5.14. Maze Therapeutics, Inc. has a one year low of $6.71 and a one year high of $53.65. The company has a 50-day moving average of $44.79 and a 200 day moving average of $37.94.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on MAZE. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Wedbush lifted their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a report on Monday, March 16th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics has an average rating of “Buy” and a consensus price target of $66.44.
Check Out Our Latest Report on MAZE
Hedge Funds Weigh In On Maze Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of MAZE. Janus Henderson Group PLC lifted its stake in shares of Maze Therapeutics by 318.0% during the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. grew its stake in Maze Therapeutics by 218.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter. Marshall Wace LLP grew its stake in Maze Therapeutics by 3,868.5% in the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares during the last quarter. Caligan Partners LP bought a new position in Maze Therapeutics in the 4th quarter valued at about $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new stake in Maze Therapeutics during the third quarter worth approximately $14,135,000.
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Further Reading
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
